Literature DB >> 11130233

Gamma-hydroxybutyrate (GHB): a newer drug of abuse.

T O'Connell1, L Kaye, J J Plosay.   

Abstract

Gamma-hydroxybutyrate (GHB) is an illicitly marketed substance that has recently gained popularity among body builders and party attendees as a drug of abuse. GHB is a depressant that acts on the central nervous system. It is purported as a strength enhancer, euphoriant and aphrodisiac and is one of several agents reported as being used as a "date rape" drug. Because of its central nervous system depressant effects, GHB can be lethal when combined with alcohol or other depressants. Currently, there is no accepted medical use for GHB, and the U.S. Food and Drug Administration has prohibited its manufacture and sale. Clinicians should be familiar with the typical clinical presentation of GHB and its adverse effects. In addition, patients should be warned of its potential toxicity and be cautioned to avoid the use of GHB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130233

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  5 in total

1.  Following the trace of elusive amines.

Authors:  R T Premont; R R Gainetdinov; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Environmental alterations of epigenetics prior to the birth.

Authors:  Chiao-Ling Lo; Feng C Zhou
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

4.  Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons.

Authors:  Elise M Weerts; Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson
Journal:  Psychopharmacology (Berl)       Date:  2005-01-12       Impact factor: 4.530

5.  Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2009-06-20       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.